To the Editor: Ray et al. (Dec. 30 issue)1 are to be complimented on their arguments in favor of changing the way we evaluate drugs after they have been approved for clinical use. As clinical pharmacologists, we strongly endorse their proposals for more research in this area and for a national center for the evaluation of new drugs. Independently, we arrived at similar conclusions and have proposed the creation of centers for education and research in therapeutics2. The concept of an independently funded center that could conduct research on drugs is not new. An important opportunity was lost in.
ASJC Scopus subject areas